Roger Jeffs, Ph.D. joined Liquidia as its CEO in 2022 after serving on the company’s Board of Directors beginning in 2020. In addition, Roger is the Vice-Chairman and Co-Founder of Kryia Therapeutics, a company focused on accelerating the development of innovative gene therapy programs for both rare and prevalent diseases. He currently serves on the Boards of Liquidia (LQDA) and Axsome Therapeutics (AXSM), and previously served on the Board of Directors of United Therapeutics (UTHR) from 2001-2016, Dova Pharmaceuticals (DOVA) from 2017-2019, Sangamo Therapeutics (SGMO) from 2017-2019, Axovant Gene Therapies (AXGT) from 2017-2019, and Albireo Pharma (ALBO) from 2017-2021.
Roger retired as President & Co-CEO of United Therapeutics Corporation in 2016 after an 18-year tenure. He joined United Therapeutics during its start-up phase in 1998 as director of research, development and medical, and served as its President and Chief Operating Officer from 2001 to 2014, and President & Co-CEO from 2015-2016. While at United Therapeutics, Roger helped lead its IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a >20% CAGR, a $1.5B annual revenue run rate and a $8B peak market cap. During his tenure, United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work. Previous to his roles at United Therapeutics, Roger held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co.
In 2015, Roger received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in "recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children." He holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.
What is Roger Jeffs' net worth?
The estimated net worth of Roger Jeffs is at least $15.90 million as of January 14th, 2025. Jeffs owns 1,019,177 shares of Liquidia stock worth more than $15,899,161 as of March 26th. This net worth evaluation does not reflect any other investments that Jeffs may own. Additionally, Jeffs receives a salary of $1,320,000.00 as CEO at Liquidia. Learn More about Roger Jeffs' net worth.
What is Roger Jeffs' salary?
How do I contact Roger Jeffs?
The corporate mailing address for Jeffs and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at ir@liquidia.com. Learn More on Roger Jeffs' contact information.
Has Roger Jeffs been buying or selling shares of Liquidia?
In the last ninety days, Roger Jeffs has sold $263,200.54 of Liquidia stock. Most recently, Roger Jeffs sold 22,343 shares of the business's stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a transaction totalling $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares of the company's stock, valued at $12,005,905.06. Learn More on Roger Jeffs' trading history.
Who are Liquidia's active insiders?
Are insiders buying or selling shares of Liquidia?
In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 150,000 shares worth more than $1,426,500.00. In the last year, insiders at the sold shares 31 times. They sold a total of 133,327 shares worth more than $1,616,512.79. The most recent insider tranaction occured on January, 27th when insider Jason Adair sold 445 shares worth more than $6,319.00. Insiders at Liquidia own 30.1% of the company.
Learn More about insider trades at Liquidia. Information on this page was last updated on 1/27/2025.
